openPR Logo
Press release

Primary Progressive Multiple Sclerosis Pipeline Assessment (2024 Updates): EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | AB Science, Sanofi, Medici Nova, MedDay Pharma, Roche, Mapi Pharma, Atara Biotherapeu

05-09-2024 04:59 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Primary Progressive Multiple Sclerosis Pipeline

Primary Progressive Multiple Sclerosis Pipeline

(Albany, USA) As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Primary Progressive Multiple Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Primary Progressive Multiple Sclerosis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Progressive Multiple Sclerosis Therapeutics Market.

The report provides a detailed description of the Primary Progressive Multiple Sclerosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Primary Progressive Multiple Sclerosis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Primary Progressive Multiple Sclerosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Primary Progressive Multiple Sclerosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Progressive Multiple Sclerosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Primary Progressive Multiple Sclerosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Primary Progressive Multiple Sclerosis treatment market.

Learn More about the Clinical and Commercial Development Activities in the Primary Progressive Multiple Sclerosis Therapeutics Domain @
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Primary Progressive Multiple Sclerosis Therapeutics Analysis
Around 10+ noteworthy pharma and biotech companies are actively involved in the development of therapies for Primary Progressive Multiple Sclerosis (PPMS). Among these, certain companies stand out due to their advancement in the development pipeline, particularly in the most advanced stage-Phase III clinical trials.

Primary Progressive Multiple Sclerosis Companies in the Therapeutics Market Include:
• Atara Biotherapeutics
• AB Science
• Sanofi
• Medici Nova
• MedDay Pharma
• Roche
• Mapi Pharma
• Brainstorm-Cell Therapeutics
And Many Others

Emerging and Marketed Primary Progressive Multiple Sclerosis Therapies Covered in the Report Include:
• Tolebrutinib: Sanofi
• ATA 188: Atara Biotherapeutics
• Masitinib: AB Science
And Many More

Get an in-depth Assessment of the Emerging Therapies and Primary Progressive Multiple Sclerosis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Primary Progressive Multiple Sclerosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Primary Progressive Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Primary Progressive Multiple Sclerosis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Primary Progressive Multiple Sclerosis Current Treatment Patterns
4. Primary Progressive Multiple Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Progressive Multiple Sclerosis Late-Stage Products (Phase-III)
7. Primary Progressive Multiple Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Progressive Multiple Sclerosis Discontinued Products
13. Primary Progressive Multiple Sclerosis Product Profiles
14. Primary Progressive Multiple Sclerosis Companies
15. Primary Progressive Multiple Sclerosis Drugs
16. Dormant and Discontinued Products
17. Primary Progressive Multiple Sclerosis Unmet Needs
18. Primary Progressive Multiple Sclerosis Future Perspectives
19. Primary Progressive Multiple Sclerosis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tumor-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/reactive-arthritis-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Progressive Multiple Sclerosis Pipeline Assessment (2024 Updates): EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | AB Science, Sanofi, Medici Nova, MedDay Pharma, Roche, Mapi Pharma, Atara Biotherapeu here

News-ID: 3491363 • Views:

More Releases from DelveInsight Business Research

Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therapies from 10+ key Players, says DelveInsight
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape. DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD 5.2 billion by 2032, analyses DelveInsight
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion by 2032, analyses DelveInsight
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billion by 2032, analyses DelveInsight
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced

All 5 Releases


More Releases for Primary

Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships. Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk